Ezscan——一种无创检测糖尿病心血管自主神经并发症的新技术

目的 研究Ezscan在评估糖尿病心脏自主神经功能中的价值.方法 144例2型糖尿病患者,检测血脂、HbA1c用Holter检测心率变异性,用经典试验检测糖尿病心血管自主神经病变,并使用Ezscan检测糖尿病并发症的风险.结果 在Holter的频谱分析中,低频区(LF)的测量值与Ezscan数据相关(r=0.39,P＜0.01),LF/HF与Ezscan亦相关(r=0.28,P＜0.01).而Holter测量的其他数值与Ezscan的相关性较弱.HbA1c与LF无相关性.与经典试验相比,Ezscan的敏感度为58.3%,特异度为57.8%.结论 Ezscan检查是一种有价值的、可行的筛查糖尿病并发症的方法,与其他检测自主神经功能的试验相比更加快速及简便.

Abstract：

Objective To assess the efficacy of Ezscan in evaluating the risk of cardiac autonomic neuropathy (CAN) in diabetes. Methods This study included 144 patients with diabetes. Their serum lipid profile and HbA1c were determined. The heart rate variability was assessed by Holter, and the cardiac autonomic neuropathy by classic experiments. Meanwhile, Ezscan was carried out. Results There was a positive correlation between low frequency (LF) measurements by Holter and Ezscan score( r=0. 39, P＜0. 01 ), so did LF/HF and Ezscan score( r=0. 28, P＜0. 01 ). Correlations between Ezscan score and other Holter parameters were weaker. There was no correlation between HbA1c and LF measurements. In patients with positive classic experiments, the sensitivity and specificity of Ezscan were 58. 3% and 57.8% respectively. Conclusions Ezscan test is a valuable screening procedure for detecting diabetic complications. It is more facilitative and takes shorter time than does the classical autonomic function assessment.

Ezscan: A new non-invasive technology to evidence cardiac autonomic neuropathy in diabetes

Objective To assess the efficacy of Ezscan in evaluating the risk of cardiac autonomic neuropathy (CAN) in diabetes. Methods This study included 144 patients with diabetes. Their serum lipid profile and HbA1c were determined. The heart rate variability was assessed by Holter, and the cardiac autonomic neuropathy by classic experiments. Meanwhile, Ezscan was carried out. Results There was a positive correlation between low frequency (LF) measurements by Holter and Ezscan score( r=0. 39, P＜0. 01 ), so did LF/HF and Ezscan score( r=0. 28, P＜0. 01 ). Correlations between Ezscan score and other Holter parameters were weaker. There was no correlation between HbA1c and LF measurements. In patients with positive classic experiments, the sensitivity and specificity of Ezscan were 58. 3% and 57.8% respectively. Conclusions Ezscan test is a valuable screening procedure for detecting diabetic complications. It is more facilitative and takes shorter time than does the classical autonomic function assessment.